Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 3/2019

Content (16 Articles)

NSCLC Review

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors

Ernest Nadal, Bartomeu Massuti, Manuel Dómine, Rosario García-Campelo, Manuel Cobo, Enriqueta Felip

Open Access Original Article

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma

Boyang Chang, Tao Huang, Huajun Wei, Lujun Shen, Duo Zhu, Wenjun He, Qifeng Chen, Huihua Zhang, Yunjian Li, Ruopan Huang, Wang Li, Peihong Wu

Original Article

CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions

Wanghong Hu, Zhenguo Zi, Yanling Jin, Gaoxin Li, Kang Shao, Qiliang Cai, Xiaojing Ma, Fang Wei

Original Article

Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model

Diana Llopiz, Marta Ruiz, Lorea Villanueva, Tamara Iglesias, Leyre Silva, Josune Egea, Juan J. Lasarte, Perrine Pivette, Véronique Trochon-Joseph, Bérangère Vasseur, Graham Dixon, Bruno Sangro, Pablo Sarobe

Original Article

Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-γ

Lin Lin, Patricia Rayman, Paul G. Pavicic Jr., Charles Tannenbaum, Thomas Hamilton, Alberto Montero, Jennifer Ko, Brian Gastman, James Finke, Marc Ernstoff, C. Marcela Diaz-Montero

Original Article

Identification and characterization of an alternative cancer-derived PD-L1 splice variant

Nadia B. Hassounah, Venkat S. Malladi, Yi Huang, Samuel S. Freeman, Ellen M. Beauchamp, Shohei Koyama, Nicholas Souders, Sunil Martin, Glenn Dranoff, Kwok-Kin Wong, Chandra S. Pedamallu, Peter S. Hammerman, Esra A. Akbay

Open Access Original Article

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

Kathleen M. Mahoney, Sachet A. Shukla, Nikolaos Patsoukis, Apoorvi Chaudhri, Edward P. Browne, Arnon Arazi, Thomas M. Eisenhaure, William F. Pendergraft III, Ping Hua, Hung C. Pham, Xia Bu, Baogong Zhu, Nir Hacohen, Edward F. Fritsch, Vassiliki A. Boussiotis, Catherine J. Wu, Gordon J. Freeman

Open Access Original Article

Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I–III colon cancer

Rui Zhou, Jingwen Zhang, Dongqiang Zeng, Huiying Sun, Xiaoxiang Rong, Min Shi, Jianping Bin, Yulin Liao, Wangjun Liao

Original Article

Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater

Min Hwan Kim, Mi Jang, Hoguen Kim, Woo Jung Lee, Chang Moo Kang, Hye Jin Choi

Melanoma Original Article

The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice

Hussein Sultan, Takumi Kumai, Toshihiro Nagato, Juan Wu, Andres M. Salazar, Esteban Celis

CD73 expression in normal and pathological human hepatobiliopancreatic tissues

Amedeo Sciarra, Inês Monteiro, Christine Ménétrier-Caux, Christophe Caux, Benoit Gilbert, Nermin Halkic, Stefano La Rosa, Pedro Romero, Christine Sempoux, Laurence de Leval

Original Article

Chronic retroviral infection of mice promotes tumor development, but CD137 agonist therapy restores effective tumor immune surveillance

Anna Malyshkina, Elisabeth Littwitz-Salomon, Kathrin Sutter, Jean Alexander Ross, Annette Paschen, Sonja Windmann, Simone Schimmer, Ulf Dittmer

Original Article

STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes

Morten Nørgaard Andersen, Anders Etzerodt, Jonas H. Graversen, Lisa C. Holthof, Søren K. Moestrup, Marianne Hokland, Holger J. Møller

Open Access Kidney Cancer Original Article

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial

Charlotte M. Huijts, Sinéad M. Lougheed, Zuhir Bodalal, Carla M. van Herpen, Paul Hamberg, Metin Tascilar, John B. Haanen, Henk M. Verheul, Tanja D. de Gruijl, Hans J. van der Vliet

Open Access Clinical Trial Report

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

Alberto A. Chiappori, Charles C. Williams, Jhanelle E. Gray, Tawee Tanvetyanon, Eric B. Haura, Ben C. Creelan, Ram Thapa, Dung-Tsa Chen, George R. Simon, Gerold Bepler, Dmitry I. Gabrilovich, Scott J. Antonia

Correction

Correction to: CD73 expression in normal and pathological human hepatobiliopancreatic tissues

Amedeo Sciarra, Inês Monteiro, Christine Ménétrier-Caux, Christophe Caux, Benoit Gilbert, Nermin Halkic, Stefano La Rosa, Pedro Romero, Christine Sempoux, Laurence de Leval

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine